Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total transaction of $2,358,215.08. Following the completion of the sale, the chief operating officer now directly owns 751,243 shares of the company’s stock, valued at approximately $26,173,306.12. This trade represents a 8.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total transaction of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.35, for a total value of $1,986,613.45.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $31.96 on Friday. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The business’s 50 day moving average is $39.85 and its two-hundred day moving average is $29.27. The stock has a market capitalization of $7.10 billion, a P/E ratio of 72.63 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HIMS. Citigroup reaffirmed a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Piper Sandler increased their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.